Zudena (udenafil) is a phosphodiesterase type 5 (PDE5) inhibitor specifically developed for the treatment of erectile dysfunction (ED). It functions by enhancing blood flow to the penile tissues, facilitating a firm and sustainable erection when sexual stimulation occurs. This medication is distinguished by its rapid onset of action and prolonged duration, offering a reliable therapeutic window for sexual activity. Clinical studies support its efficacy and favorable safety profile, making it a trusted option for physicians managing male sexual health disorders.

Features

• Active ingredient: Udenafil 100 mg
• Pharmacological class: Selective phosphodiesterase type 5 (PDE5) inhibitor
• Onset of action: As early as 30 minutes post-administration
• Duration of efficacy: Up to 12 hours
• Administration: Oral tablet, taken with or without food
• Manufacturer compliance: GMP-certified production

Benefits

• Provides a rapid and reliable erectile response, enhancing sexual confidence and spontaneity.
• Sustained therapeutic window allows for greater flexibility in timing intimate activity.
• Demonstrated high efficacy across various ED severities and etiologies, including diabetic and post-prostatectomy patients.
• Generally well-tolerated with a lower incidence of visual disturbances compared to some other PDE5 inhibitors.
• Does not require strict fasting conditions for administration, improving patient convenience and adherence.

Common use

Zudena is prescribed for the management of erectile dysfunction in adult males. It is suitable for patients with organic, psychogenic, or mixed etiology ED. It may also be used in cases where other PDE5 inhibitors have been ineffective or poorly tolerated, following appropriate medical evaluation. It is not indicated for use in women, children, or adolescents.

Dosage and direction

The recommended dose is 100 mg taken orally approximately 30–60 minutes before anticipated sexual activity. Do not exceed one dose in a 24-hour period. The tablet may be taken with or without food, though high-fat meals may delay onset of action. Dosage adjustment may be necessary for patients with hepatic impairment, severe renal impairment, or those taking certain concomitant medications—always follow prescribing physician guidance.

Precautions

Prior to initiating treatment, patients should undergo a thorough medical assessment to evaluate cardiovascular status, as sexual activity carries potential cardiac risk. Use with caution in patients with anatomical penile deformities, predisposition to priapism, bleeding disorders, or active peptic ulceration. Avoid concurrent use with other ED treatments or recreational erectogenic agents. Not recommended for use in men for whom sexual activity is inadvisable.

Contraindications

Zudena is contraindicated in patients with a known hypersensitivity to udenafil or any excipients in the formulation. Concurrent administration with nitrates or nitric oxide donors in any form is strictly prohibited due to the risk of severe hypotension. It is also contraindicated in patients with severe hepatic impairment, end-stage renal disease requiring dialysis, or a history of non-arteritic anterior ischemic optic neuropathy (NAION).

Possible side effect

Common adverse reactions include headache, flushing, nasal congestion, dyspepsia, and dizziness. Less frequently, myalgia, back pain, and insomnia may occur. Visual disturbances such as blurred vision or altered color perception are possible but rare. Priapism (prolonged and painful erection) is a serious though uncommon side effect requiring immediate medical intervention to avoid permanent tissue damage.

Drug interaction

Concomitant use with nitrates (e.g., nitroglycerin, isosorbide mononitrate) is absolutely contraindicated. Caution is advised with alpha-blockers, antihypertensives, and strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir), which may increase udenafil plasma concentrations. Moderate interactions are possible with alcohol, grapefruit juice, and other PDE5 inhibitors. Always disclose all current medications to the prescribing physician.

Missed dose

Zudena is taken on an as-needed basis; it does not follow a daily dosing schedule. If a dose is missed, it may be taken when remembered, provided that sexual activity is planned and at least 24 hours have passed since the last dose. Do not double the dose to make up for a missed one.

Overdose

In case of suspected overdose, seek immediate medical attention. Symptoms may include severe headache, profound hypotension, syncope, or prolonged erection. Standard supportive measures should be applied; haemodynamic support may be necessary. Priapism requires urgent urological intervention to prevent irreversible complications. Dialysis is not expected to significantly enhance elimination.

Storage

Store at room temperature (15–30°C) in the original container, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Dispose of unused or expired medication in accordance with local regulations, preferably via a pharmacy take-back program.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any new medication or making changes to an existing treatment plan. Do not disregard or delay seeking medical advice based on content provided here.

Reviews

Clinical trials and post-marketing surveillance indicate high patient satisfaction with Zudena, particularly noting its rapid onset and extended duration of action. Many users report improved erectile function and overall sexual satisfaction. Healthcare professionals appreciate its predictable pharmacokinetics and generally favorable side effect profile. Individual experiences may vary; always follow the guidance of a prescribing physician.